TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: maximum percent reduction in DEX dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of myopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery from benign paroxysmal positional vertigo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROCK activity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain reduction measured by CHEOPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bedsores prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quitting smoking after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of sCD163
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Weight to height ratio (WHtR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of IFG/IGT/T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of blocks achieving surgical anaesthesia without supplemental analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to perform the block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient satisfaction with anaesthetic infiltration
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Surgeon's overall satisfaction with technique
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADFT (defibrillation threshold)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Signal amplitude detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Analgesia at rest (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative requirements of buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of PD‐1 and CD95 molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Root-mean-square difference of successive normal RR intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAS score at coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total morphine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long term cognitive outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long term physical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal work capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to in-field progression
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of acute esophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of chronic esophageal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Aldrete score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-procedural major complications
Endpoint domain: Adverse events/effects
Primary endpoint: Combined MACE incidence rates
Endpoint domain: Mortality/survival
Primary endpoint: Rate of rehospitalization for heart failure or death
Endpoint domain: Mortality/survival
Primary endpoint: Social Functioning Scale improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Scale for the Assessment of Negative Symptoms reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of anti‐S. cerevisiae mannan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resting myocardial blood flow (MBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Walking ability improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: alerting performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival rate at 3 and 6 months
Endpoint domain: Mortality/survival
Primary endpoint: alcohol abstinence rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: post sham exposure symptoms among participants with high pre-existing anxiety
Endpoint domain: Adverse events/effects
Primary endpoint: ≥50% decrease in depression score over baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: social well-being
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Rate of preterm birth at </= 32 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Admissions into the neonatal intensive care unit (NICU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of NICU stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in the frequency of smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with information form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: allogeneic blood transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: costs related to PAD and pharmacologic administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IL-6 blood concentration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recovery of flow expiratory volume in one second %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma Volume (PV) restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spirometry improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: asthma symptom scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative abundance of Faecalibacterium prausnitzii
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha-diversity of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTCT rate
Endpoint domain: Mortality/survival
Primary endpoint: Fear-avoidance beliefs score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle endurance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthcare utilization reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image interpretation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FVC changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Implant stability quotient (ISQ) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to achieve ISQ ≥ 70
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D (diffusion coefficient)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: f (fractional volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and function of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKDC symptom-activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ligament laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical improvement of acne scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dermal collagen increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procollagen type I gene upregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotional functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: Treatment success by PUCAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in drug and alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apolipoprotein B‐48 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chylomicron size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exogenous lipid oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of newly formed bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of fasciculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of fasciculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cord blood tissue plasminogen activator antigen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Consumption of tramadol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ZAP with NRS > 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative pain and discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfactory results and healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative failure rate at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in anxiety diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ephedrine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Emetic effects frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of prescriptions in line with guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in coagulation/anti-coagulation measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: impact of diabetes management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PPL response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incretin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of target LDL-C and TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of cardiovascular disease events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of nonfatal myocardial infarction, stroke, or death from cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cure rate at end of follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: saliva sulfapyridine appearance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: EuroQuol5D visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Participation Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Modified Capability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cough incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDM competences and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aneurysm-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Neurodevelopmental impairment or death
Endpoint domain: Mortality/survival
Primary endpoint: frequency of bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: leg vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MBEST score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uniform ground reaction force curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OC continuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STI rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of breath holding
Endpoint domain: Adverse events/effects
Primary endpoint: Serum levels of APN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of AdipoR1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose-lowering activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of plaque embolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Response rate on BDD-YBOCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of prescriptions of penicillins for RTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of trimethoprim/sulfamethoxazole prescriptions for uncomplicated lower UTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of overall responders based on patient-rated assessments of IBS-C symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hospitalizations after 12 months
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: weekly changes in nicotine craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subsequent decreases in stimulant craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subsequent increases in nicotine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROP requiring laser treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Cholestasis development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma DHA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sustained participation in the program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in skin scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mydriasis maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral hygiene compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding index (BI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance covered on ISWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total score at the end of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of proinflammatory cytokines (IL-1beta and TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Process of recolonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of non-vertebral fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of instrumental deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total IgE level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in management of laryngospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in management of SVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hyponatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rest HI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adjusted flow at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to identification of the epidural space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function (WAIS Digit Span performance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety (HAM-A and STAI measures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dysbiosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in fitness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of bacterial vaginosis (BV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vaginal colonization with Lactobacillus species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Activated Clotting Time (ACT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activated Partial Thromboplastin Time (aPTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: propofol dose requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-colonoscopy pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Walking distance (6-m walk test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory volume (VolIn) of the target lobe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in crimes against persons
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in property offenses
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Inter-day reproducibility of LTH plateau
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correlation between LDF and LSCI measurements of PORH peak CVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Telangiectasia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment-related pain scores
Endpoint domain: Adverse events/effects
Primary endpoint: Patient preference for LPDL over IPL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Craving intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for completion of the 30 km trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of postoperative chronic pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cancer history
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Absolute gentamicin lung bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mass median aerodynamic diameter (MMAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fine particle doses (FPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage of time at pH less than 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of transient LOS relaxations associated with reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ocular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safer Sex action scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of unprotected sex acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient-relevant physical activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of NSAID tablets in the first week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain scores from week four to eight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant-Murley score and ROM after six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes